OUR HISTORY

As you can see by the timeline, breaking through is an Eisai tradition. But what matters most isn’t what we’ve achieved. It’s how we continually strive to create hope through innovations that improve the lives of the patients and families we serve.

MAJOR MILESTONES IN human health care HISTORY

  • 1987 EISAI ARRIVES IN U.S.
    We came to America with one goal in mind: to create innovative new medicines to help patients.
  • 1993 BIRTH OF
    human health care
    For the first time in pharmaceutical history, a company defined its primary mission as giving first thought to patients and their families, and to increasing the benefits that health care provides.
  • 1997 LEADING THE FIGHT AGAINST ALZHEIMER’S DISEASE
    We launched our first product in the U.S. — a neurology treatment destined to become the standard therapy for Alzheimer’s disease.
  • 2007 TRANSFORMING ANTIBODIES INTO ANTI-CANCER AGENTS
    Eisai acquired Morphotek, Inc., to bolster development of monoclonal antibodies, and potentially help boost cancer patients’ immune response. Part of Morphotek subsequently evolved into the Epochal Precision Anti-Cancer Therapeutics (EPAT) research center.
  • 2010 HELPING CANCER PATIENTS
    Inspired by Nature and our human health care mission, our scientists developed a cancer treatment derived from a sea sponge compound that showed strong anti-tumor activity.
  • 2011 INVESTING IN THE FUTURE OF ONCOLOGY
    Eisai invested over $200 million to launch H3 Biomedicine (H3). This vanguard biopharmaceutical company leverages insights from cancer genomics and real-life patient data to break through with novel cancer therapies.
  • 2014 STRIVING FOR CONVULSIVE SEIZURE
    FREEDOM
    We discovered and developed a therapy that targets excitatory signals in the brain. It can potentially help thousands of patients suffering from convulsive seizures.
  • 2014 COLLABORATING WITH BIOGEN TO DEVELOP AND COMMERCIALIZE NEW ALZHEIMER THERAPIES
    Through collaboration with Biogen, we advanced our development and commercialization of next-generation Alzheimer’s disease treatments. In 2017, we expanded that existing agreement to further the development of investigational therapies. Together, we hope to maximize the benefits for patients and their families.
  • 2018 COLLABORATING WITH MERCK ON COMBINATION ONCOLOGY THERAPIES
    So far, treatments combining Eisai’s and Merck’s therapies have received three Breakthrough Therapy designations from the FDA. And there may be more to come: we're currently evaluating the combination in 13 tumor types across 20 clinical trials.
  • 2019 PIONEERING ANTI-CANCER PRECISION MEDICINE
    With the opening of our Epochal Precision Anti-Cancer Therapeutics (EPAT) research center, we strengthened our focus on developing oncology drugs that specifically target cancer cells. EPAT’s pioneering work in precision medicine utilizes our unique Antibody-Drug Conjugate (ADC) technology, biospecifics and other emerging biologics.
  • 2019 HARNESSING HUMAN GENETICS TO BATTLE DEMENTIAS
    We established the Eisai Center for Genetics Guided Dementia Discovery (G2D2) to accelerate the discovery of breakthrough therapeutics for patients and families living with dementia. G2D2 leverages the combined power of human genetics, data sciences and precision chemistry in the fight to eradicate Alzheimer’s disease and other dementias.
  • 2020 BREAKING THROUGH FOR PATIENTS WITH INSOMNIA
    Our commitment to human health care can mean going beyond traditional treatments. That is why, in addition to a new treatment option, we are providing online support tools to patients with insomnia. Because we believe, all people deserve a good night’s sleep.
  • 2022 NEW U.S. HEADQUARTERS
    Our new Eisai Inc. headquarters at 200 Metro Blvd., Nutley, NJ, brings all of our New Jersey-based employees together in one workplace designed to foster extensive employee engagement and collaboration. 200 Metro drives a culture of new scientific horizons and entrepreneurial innovation.
  • 2023 A TREATMENT FOR ALZHEIMER’S DISEASE
    The U.S. Food and Drug Administration (FDA) granted under the Accelerated Approval Pathway our treatment for Alzheimer’s disease (AD). This treatment is an exciting step forward in our ongoing mission to help alleviate the challenges faced by those living with AD.